Comparing VectivBio (NASDAQ:VECT) and Senti Biosciences (NASDAQ:SNTI)

Senti Biosciences (NASDAQ:SNTI) and VectivBio (NASDAQ:VECT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk.

Profitability

This table compares Senti Biosciences and VectivBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-154.84%	-77.42%
VectivBio	N/A	N/A	N/A

Institutional & Insider Ownership

25.7% of Senti Biosciences shares are held by institutional investors. 15.9% of Senti Biosciences shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Senti Biosciences and VectivBio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$2.56 million	7.19	-$71.06 million	($15.56)	-0.26
VectivBio	$27.34 million	20.97	-$93.74 million	N/A	N/A

Senti Biosciences has higher earnings, but lower revenue than VectivBio.

Risk & Volatility

Senti Biosciences has a beta of 2.69, suggesting that its share price is 169% more volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Senti Biosciences and VectivBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	0	0	1	0	3.00
VectivBio	0	0	0	0	0.00

Senti Biosciences presently has a consensus target price of $10.00, suggesting a potential upside of 149.38%. Given Senti Biosciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Senti Biosciences is more favorable than VectivBio.

Summary

Senti Biosciences beats VectivBio on 7 of the 11 factors compared between the two stocks.

About Senti Biosciences

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About VectivBio

VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.